Statement: Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial.
Primary_evidence: INTERVENTION 1:    Arm 1: Yoga Intervention   Yoga Intervention   Yoga: Yoga sessions INTERVENTION 2:    Arm 2: Educational Wellness Group   Educational Wellness Group   Education: Educational Wellness Group
Secondary_evidence: INTERVENTION 1:    Arm A: Endocrine Therapy (ET)   Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.   Letrozole Fulvestrant INTERVENTION 2:    Arm B: ET With Bevacizumab (ET-B)   Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.   Letrozole   Bevacizumab Fulvestrant